Shy, secretive world of bees
The diversity of bee existence in India was underscored by observations by the naturalist, Arun Bansal, of these insects 'unusually' pouring out of dark hollows in the roots of a tree at the Panjab University's (PU) Dr PN Mehra Botanical Gardens and from a secretive hole in a reddish wall at the Teachers' Flats. The entrance to the cavity nests was small and thus easier guarded against predators such as ants, hornets, wasps, birds and humans. There were multiple hives within. These were not the typical, huge hives one associates hanging in the open from trees, underneath the eaves of buildings and ceilings of tall water tanks etc, and which are formed by the famous Rock honey bee (Apis dorsata). These big Rock bees are the ones infamous for delivering dreaded stings when disturbed.
On the other hand, the honey bees coming out of the PU tree and wall cavity were smaller than the Rock bees. I sought their identification from professor Pardeep Chhuneja, an award-winning apiculture scientist and former head, department of entomology, Punjab Agricultural University (PAU), Ludhiana. 'It is the native species, Apis cerena cerena (Asian honey bee), in the tree roots and wall of PU. Along with the Apis mellifera (Western honey bee), which is an imported bee for apiculture, these two species are cavity-dwelling ones. These two species are the ones used for beekeeping in India,' Chhuneja told this writer.
Scientific research has established that the Apis cerena can forage as far as 1.5-2.5 km from the hive. They gather nectar and pollen from the flowers. Nectar is turned into honey by these 'flying Lilliputians of the natural world' and is stored to provide energy in the guise of carbohydrates for adults and larvae of the bee colony. Honey-making is not an enterprise that nature has predestined for human lip-smacking but is actually for the benefit of the bees themselves. Some forest department employees criminally smoke out, destroy and displace hives of wild Rock honey bees under their protection in wildlife sanctuaries. They steal honey from the mouths of the hungry little ones to oblige senior officers/VIPs by delivering honey jars to official residences.
Bees are remarkable, cooperative creatures but we know little of them beyond...delicious honey...and more vaguely as pollinators. Honey bees are able to maintain temperatures with tolerable limits even when the outside temperatures range from freezing point to searing heat. This task is carried out by the fanning bees which stand at the 'doorway to their hive and produce a current of air by beating their wings, which serves to air condition the hive'.
The Apis cerena (AC) resorts to various colony defensive behaviours to ward off predators, such as abdomen shaking, hissing (through wing vibrations) and group defence (including grasping, pulling, and biting, killing by overheating). 'Heat balling is a unique defence of AC to kill predatory hornets. Several hundred bees surround the hornet in a tight ball and vibrate their thoracic muscles to produce heat. The AC workers are able to raise the temperature inside the ball to an average of 46°C for approximately 20 minutes. This is high enough to kill the hornet inside, but not high enough to kill the bees, who can tolerate temperatures up to 48°C and 50°C,' states a research paper, Comparative Study of Apis cerena and Apis mellifera, by DR Katuwal, Alina Pokhrel and Dipak Khanal.
vjswild2@gmail.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
8 hours ago
- Time of India
PAU defends GM maize trials, says its only for research
Ludhiana: In the wake of opposition from NGOs over field trials of genetically modified (GM) maize in Punjab at Punjab Agricultural University (PAU), the varsity defended its decision to proceed with research trials. The university clarified that it was not releasing GM maize for commercial use but only conducting scientific research, as per its institutional mandate and SOPs outlined by the department of biotechnology. The GM maize in question has been developed by agri-science company, Bayer. The crop has been genetically engineered with both herbicide-tolerant (HT) and insect-resistant Bacillus thuringiensis (BT) traits. Bayer applied to the Government of India's department of biotechnology for permission to conduct bio-safety trials under the statutory review committee on genetic manipulation (RCGM). The trials are being conducted in accordance with biosafety research level I (BRL-I) which are preliminary and advanced level II (BRL-II) norms. Environmentalists, along with a coalition of GM Free India, have raised serious objections to the Punjab government issuing the NoC for genetically modified maize trials. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it legal? How to get Internet without paying a subscription? Techno Mag Learn More Undo The coalition has written to the Punjab agriculture minister, urging him to immediately institute an inquiry into the scientific basis on which such an NoC was issued and sought its withdrawal. Trying to quell criticism, PAU vice-chancellor Dr Satbir Singh Gosal clarified that the university was not releasing GM maize for cultivation and had no role in its commercialisation. "We are not releasing this crop. That is the job of the government. PAU is only carrying out scientific research. Our mandate is to test and evaluate new technologies in agriculture so that policy makers, farmers, and society can make informed decisions based on science, not speculation," he said. NGOs against GM-free crops have expressed apprehensions of potential long-term ecological and health consequences of the adoption of GM crops. They have demanded a halt to all trials after Punjab government issued NoC for trials last month. However, PAU asserted that such assessments could not be made without data. "We cannot say whether any new crop, GM or not, is good or bad unless we research it," Dr Gosal said. "These are controlled, limited research trials under strict regulatory frameworks of the department of biotechnology," he added. Before the trials began, the project was reviewed and cleared by a Punjab-level committee consisting of officials from the Punjab department of agriculture, Punjab State Council for Science & Technology, biotechnology incubator, state health department and PAU scientists. The committee examined all safety protocols and agreed that the trials could be conducted under strict monitoring adhering to the norms. PAU officials stressed that the university has a long record of research on transgenic crops and has been evaluating GM crops, including BT cotton. Officials also pointed to the university's rejection of nano urea, a product that was widely promoted by all sections, including the central government. "We tested nano urea in our research fields and found it ineffective in Punjab's soil and crop conditions. We did not recommend it. Now, even the central government is rethinking it. That shows the importance of independent, university-led research," the vice-chancellor said. More than 30 countries, including the United States and Canada are growing GM crops. In India, BT cotton, despite initial opposition and widespread myths, has now been widely adopted and accounts for majority of cotton cultivation. "There were stories that animals died after eating BT cotton leaves. But none of those were proven scientifically. Today, BT cotton is key crop in agriculture," Dr Gosal said, adding, "We are trying to avoid repeating the same cycle of myth-based panic. We must let data speak. A growing number of farmers in Punjab have been informally demanding more advanced BT varieties such as BT 3 and BT 4, citing growing resistance to older versions. "If farmers are demanding solutions, we must investigate them scientifically first," he said.
Hans India
a day ago
- Hans India
Oral health key for cancer care, boosting survival rates: AIIMS
Oral health plays a significant role in cancer care, and increasing survival rate, according to researchers from the All India Medical Science (AIIMS). The presence of pathogenic oral bacteria such as Porphyromonas gingivalis and Prevotella intermedia has been shown to elevate cancer incidence and adversely affect overall cancer-specific and disease-free survival. In a comment published in the journal, The Lancet Regional Health - Southeast Asia, oncologists Dr. Abhishek Shankar, and Dr. Vaibhav Sahni from AIIMS stated that urged the need to boost public health initiatives as oral health can significantly influence cancer outcomes and survivorship. 'It is abundantly clear that oral healthcare plays a significant role in enhancing health-related outcomes, including those related to cancer survivorship. This evidence underscores the necessity of integrating oral health practices not only at the primary care level but throughout all healthcare settings,' the researchers said in the paper. The oncologists also cited several global studies that cited the link between oral health and cancer, particularly in head and neck cancers (HNC). The studies showed that routine dental visits over the past 10 years were associated with reduced cancer mortality. They urged for initiatives such as the toothbrushing programmes for boosting oral care and implementing oral mouthrinse- based point-of-care 3 (PoC) testing for early diagnosis of periodontal disease. 'We tried to emphasise the importance of oral health in cancer care particularly for the Southeast Asia region to promote awareness and policy-level decision-making,' Dr Shankar, Assistant Professor of Radiation Oncology at AIIMS, Delhi, told IANS. 'We want public health initiatives to be structured around oral health such as school toothbrushing programmes stand to aid not only the population at large but the exchequer as well,' he added. Further, the paper suggests sensitising and incentivising teachers and families regarding the importance of oral health, alongside providing free toothbrush and toothpaste samples to help foster behavioural change. In addition, public health interventions like nutrition and sugar warning labels may assist consumers in making informed decisions. 'Prohibiting sugar-laden foods marketed using likable characters needs to be taken up seriously at a policy level,' Dr Sahni, Scientist of Radiation Oncologat, AIIMS Delhi, told IANS. He highlighted the systemic and public health importance of oral health in cancer-related outcomes as well as emphasise the need for relevant data. The expert also called for proper studies in Southeast Asia and not a simple translation of Western findings to the region's context.
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
China's biotech surge shifts global drug innovation, stirs US tension
By Amber Tong, Jinshan Hong and Spe Chen The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way from their copycat days to challenge Western dominance on innovation. The number of novel drugs in China — for cancer, weight-loss and more — entering into development ballooned to over 1,250 last year, far surpassing the European Union and nearly catching up to the US's count of about 1,440, an exclusive Bloomberg News analysis showed. And the drug candidates from the land once notorious for cheap knock-offs and quality issues are increasingly clearing high bars to win recognition from both drug regulators and Western pharmaceutical giants. The findings, gleaned from an analysis of a database maintained by pharma intelligence solutions provider Norstella, show a fundamental shift in medical innovation's center of gravity. With President Donald Trump already threatening tariffs on the pharmaceutical sector, China's biotech advances — the scale of which is slowly coming into view — risk becoming another realm of superpower rivalry like artificial intelligence and electric vehicles. 'The scale itself is not something we've seen before,' said Helen Chen, managing partner at LEK Consulting in Shanghai, who has advised healthcare companies on their China strategy since 2003. 'The products are here, they're attractive and they're fast.' This shift has occurred at an unprecedented pace. When China began to overhaul its drug regulatory system in 2015, the country had just 160 compounds to contribute to the global pipeline of innovative drugs, or less than 6% of the total, behind Japan and the UK. The reforms helped streamline reviews, enforced data quality standards and improved transparency. The government's 'Made in China 2025' plan to elevate manufacturing in 10 priority sectors also helped spur a flurry of investments in biotechnology. Altogether, they unleashed a boom led by foreign-educated and -trained scientists and entrepreneurs. 'Not only is it now almost at parity with the US but it has that growth trajectory,' said Daniel Chancellor, vice president of thought leadership at Norstella. 'It wouldn't be sensationalist to suggest that China will overtake the US in the next few years purely in terms of numbers of drugs that it's bringing through into its pipeline.' Bloomberg News ' data analysis focuses on innovative drugs, excluding generic combinations, reformulations and biosimilars. Numbers aside, the more stunning leap is in the quality of Chinese biotech innovation. While there's constant debate in the pharmaceutical industry on whether Chinese firms are capable of producing not just effective but needle-shifting new therapies, there's growing recognition on multiple fronts. The world's strictest regulatory agencies, including the US Food and Drug Administration and the European Medicines Agency, increasingly view Chinese drugs as generally promising enough to justify devoting extra resources to speed up their review, handing them coveted industry designations such as priority review, breakthrough therapy designation or fast track status. The country is now slightly ahead of the EU in earning such expedited reviews as of 2024, the data shows, a remarkable edge over a region that previously produced drugs like Wegovy. One of the early exemplars of Chinese innovation is a cell therapy that has shown promise to potentially cure a deadly blood cancer. First developed in China by Legend Biotech Corp, it is now marketed by Johnson & Johnson — having won a few expedited review designations along the way — and considered superior to a competing US-originated therapy. Still, the absolute number of China-originated drugs winning these designations trail their US counterparts by a large margin. Risk-aversion remains a factor holding back Chinese pharmaceutical innovation: So far, top companies tend to focus on making better versions of existing therapies or new iterations of older ideas, and few are pioneering novel treatment approaches that have never been tried before — an endeavor that comes with a high risk of failure and is still led by the US, Europe and, to a lesser extent, Japan. Nevertheless, the biggest Chinese breakthroughs are increasingly being snapped up by pharmaceutical giants for record sums, a sign that the perennial competition for the next blockbuster drug is also shifting East. A novel cancer drug from Akeso Inc., which came out more effective than Merck & Co Inc.'s Keytruda in a Chinese study last year, has been likened to China biotech's DeepSeek moment, spawning a new wave of global interest. The promise of topping Keytruda, the world's top-selling drug, also swelled the valuation of Summit Therapeutics Inc, which in 2022 paid $500 million upfront for the development and marketing rights in the US and other regions. Other multinational players like Merck, AstraZeneca Plc and Roche Holding AG have also scooped up Chinese assets. In May, Pfizer Inc. set a new record as it announced a $1.2 billion upfront deal with 3SBio Inc. for a cancer drug similar to Akeso's. These deals are increasing in both value and frequency, according to biopharma deal database DealForma, signaling confidence that China-originated drugs are competitive internationally and can bring in substantial revenue. The volume of potential candidates coming out of China means multinational companies, who have a constant need to add new products to the mix, can 'cast their net wider than ever before,' Norstella's Chancellor said. A key advantage that has fueled the rise of Chinese biotech firms is their ability to conduct research cheaper and faster at every step of the way, from lab experiments and animal testing to human trials. Creating a new drug from scratch is notoriously time-consuming and expensive, and China's massive patient pool and centralized hospital network have become a significant accelerator. An analysis of the time taken for drugs to conduct various testing stages shows that doctors in China can recruit for trials much faster — for early trials for cancer and obesity drugs, they can complete patient enrollment in half the time compared to the US. The difference in costs means Chinese companies can afford to run multiple trials simultaneously to find a winner, or quickly launch new projects once a scientific idea is validated by other groups. Since 2021, China has become the top location for clinical research, initiating the largest number of new trials globally, according to GlobalData. 'They can leapfrog competitors in other countries,' said Andy Liu, head of China at Novotech Health Holdings, which helps companies run clinical trials. To be sure, clinical data in China is just a start. US regulators have made it clear that China-only trial results, no matter how positive, are not sufficient to support drug approvals. Chinese biotechs with ambition to sell their drugs overseas must prove that their treatment benefits can be replicated in non-Chinese patients, through complex and slower-moving global studies. It may still be a few years before a critical mass of drugs sourced from China wins US and EU approvals — the gold standard for high-quality treatments — and become widely used in the Western world, but many in the industry believe that's inevitable. China's innovators comprise both cutting-edge biotech startups founded by foreign-educated entrepreneurs, and old-guard Chinese pharmaceutical companies like Jiangsu Hengrui Pharmaceuticals Co., which used to be one of the country's biggest generic drugmakers. The company poured billions of dollars into shifting to innovative research and development after Beijing's campaign to lower generic drug prices made that sector less profitable. It's now the world's top-ranked pharmaceutical company for the number of new innovative drugs added to the research pipeline in the period of 2020-2024. Of the 50 companies that generated the highest number of innovative drug candidates between 2020 and 2024, 20 of them were Chinese, compared to five in the five years before. 'As we move forward, the fact that there's high quality innovation in China in terms of biotech will no longer be a novelty,' said Ali Pashazadeh, founder and managing director of healthcare advisory firm Treehill Partners in London. 'It'll just be an accepted part of the norm.' At a time when China and the US are engaged in renewed geopolitical spats, the growth of China's biotech ecosystem is causing alarm among some American politicians and business leaders. A congressional commission warned that the US risks losing its leadership position in yet another industry critical to national security. 'Biotech is one of the forefronts of the US-China tech rivalry,' said Jack Burnham, research analyst at the think tank Foundation for Defense of Democracies. In addition to economic implications and possible military applications of biotech, China's leverage on innovative therapies may be weaponized in a future conflict, he said, if Americans become dependent on those medicines. The perception of threat has spurred calls for the US government to stymie China's biotech growth — through restrictions such as export controls on scientific equipment and barriers to investment — and boost the domestic biotech sector, including by changing the regulatory environment to emulate countries where clinical trials are run more quickly. Robert F. Kennedy, the US Secretary of Health and Human Services, recently pledged to 'Make American Biotech Accelerate.' Despite the risks of the newly combative relationship between the world's two biggest economies, Chinese drugmakers like Akeso have set their sights on bringing their therapies to developed Western markets. 'The pharma industry is the best industry in the world,' Akeso Chief Executive Officer Michelle Xia said in an April interview. 'At the end of the day, what we do benefits patients in China, in the US and all around the world.'
